Biosignal granted two local patents

Sydney-based Biosignal (ASX:BOS) has been granted two additional Australian patents relating to its novel anti-bacterial technology.

"We now have four out of 13 patents approved in Australia. Having these latest two patents approved increases the likelihood of having patents approved elsewhere," said Biosignal CEO Michael Oredsson.

The first patent titled "Antimicrobial Coatings" protects surfaces (such as contact lenses and medical devices) with Biosignal's active molecules attached as well as methods for their protection.

"This is essential for our contact leans coating development," said Oredsson.

The second patent titled "Microbial Inhibitory Compositions" protects use of Biosignal's active compounds in combination with formulations used mainly in household and industrial cleaning products.

"We are doing some work in this field but it is not our core development," said Oredsson.

Biosignal's anti-microbial molecules are based on furanones secreted by the eastern Australian seaweed Delisea puilchra. The company is currently developing anti-bacterial contact lenses and a range of anti-bacterial coatings for medical devices including catheters